
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 14A
(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No.)

Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐

Check the appropriate box:

- ☐ Preliminary Proxy Statement
- ☐ **Confidential, for Use of the Commission Only** (as permitted by Rule 14a-6(e)(2))
- ☐ Definitive Proxy Statement
- ☒ Definitive Additional Materials
- ☐ Soliciting Material under §240.14a-12

Enpro Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- ☒ No fee required.
- ☐ Fee paid previously with preliminary materials.
- ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-(6)(i)(1) and 0-11
-
-
-



Enpro Inc.

5605 Carnegie Boulevard,
Suite 500
Charlotte, North Carolina 28209

**ENPRO INC.
SUPPLEMENTAL PROXY MATERIAL**

For the 2025 Annual Meeting of Shareholders to be Held on April 30, 2025

April 21, 2025

Supplemental Biographical Information

This information supplements the definitive proxy statement (the “Proxy Statement”) filed by Enpro Inc. (the “Company”) on March 24, 2025 relating to the Company’s 2025 Annual Meeting of Shareholders to be held on April 30, 2025 (the “Annual Meeting”), as supplemented by the supplemental proxy material filed by the Company on March 25, 2025 (the “March Supplement”).

The Company is providing this supplemental information solely to update the biography of Adele M. Gulfo. Ms. Gulfo is a current director standing for re-election to the Company’s Board of Directors at the Annual Meeting. On April 17, 2025, the board of directors of NewAmsterdam Pharma Company N.V. (“NewAmsterdam”), a public company, elected Ms. Gulfo to serve as a director of NewAmsterdam.

Important Information

This supplemental proxy material should be read in conjunction with the Proxy Statement as supplemented to date, including Mr. Gulfo’s full biography on page 11 of the Proxy Statement. This supplemental proxy material does not change or update any of the other information contained in the Proxy Statement or the March Supplement.
